Multipl Miyelom ve Lenfomalı Kemoterapi Alan Hastalarda Hepatit B Virüsü Reaktivasyonu ve Aşı Başarısı ile İlişkili Faktörler

Turan Erkek, Esra; Nalcaci, Meliha; KUL, AYŞE NİLGÜN

doi:10.5578/llm.20239903

Multipl Miyelom ve Lenfomalı Kemoterapi Alan Hastalarda Hepatit B Virüsü Reaktivasyonu ve Aşı Başarısı ile İlişkili Faktörler

Ayşe Nilgün KUL, (İstanbul Üniversitesi, Tıp Fakültesi, İç Hastalıkları Anabilim Dalı, Hematoloji Bilim Dalı, İstanbul, Türkiye)

Esra TURAN ERKEK, (İstanbul Üniversitesi, Tıp Fakültesi, İç Hastalıkları Anabilim Dalı, Hematoloji Bilim Dalı, İstanbul, Türkiye)

Meliha NALÇACI (İstanbul Üniversitesi, Tıp Fakültesi, İç Hastalıkları Anabilim Dalı, Hematoloji Bilim Dalı, İstanbul, Türkiye)

Türkiye'de Lösemi Lenfoma Miyelom Araştırmaları

8 8

Yıl: 2023 Cilt: 7 Sayı: 1 Sayfa Aralığı: 20 - 28 Metin Dili: Türkçe DOI: 10.5578/llm.20239903 İndeks Tarihi: 31-05-2023

Multipl Miyelom ve Lenfomalı Kemoterapi Alan Hastalarda Hepatit B Virüsü Reaktivasyonu ve Aşı Başarısı ile İlişkili Faktörler

Öz:

Amaç: Multipl miyelom veya lenfoma nedeniyle kemoterapi alan hastalarda hepatit B virüsü (HBV) reaktivasyonu ve aşı başarısı ile ilişkili faktörleri belirlemeyi ve preemptif tedavi başarısını değerlendirmeyi amaçladık. Hastalar ve Yöntem: Bu retrospektif kesitsel çalışma Aralık 2012 ile Ocak 2014 tarihleri arasında yapılmıştır. Çalışmaya multipl miyelom (n= 39) veya lenfoma (n= 35) tanısı ile sistemik kemotera- pi alan toplam 74 hasta dahil edilmiştir. Bulgular: Ortalama yaş 53.5 ± 14.8 yıldı. Reaktivasyon açısından takip edilen 28 hastanın dördünde reaktivasyon gözlendi. Dört hastanın hepsi başlangıçta HBsAg pozitifti (p< 0.001). Aşılanan 46 hastanın sadece beşinde HBsAg (hepatit B virüs yüzey antijeni) antikor pozitifliği gözlendi. HBV reaktivasyonu gelişen hastaların dördü de profilaktik lamivudin tedavisi alan hastalardı. Bu hastaların profilaktik tedavi rejimi değiştirildikten sonra HBV-DNA (hepatit B virüs deoksiribonükleik asit) ve alanin aminotransferaz (ALT) seviyeleri normale döndü ve karaciğer yetmezliği, ölüm gözlenmedi. Sonuç: HBsAg pozitif multipl miyelom veya lenfoma hastalarında kemoterapi öncesi HBsAg pozitifliği HBV reaktivasyonu ile ilişkili bulundu. Düzenli aralıklarla HBV-DNA takibi, kemoterapi sırasında HBV reaktivasyonunun erken tespiti ve antiviral tedavinin erken başlatılması açısından faydalı olabilir.

Anahtar Kelime: Hepatit B virüs reaktivasyonu Multipl miyelom Lenfoma Kemoterapi Hepatit B virüsü yüzey antijeni

Factors Associated with Hepatitis B Virus Reactivation and Vaccination Success in Patients Receiving Chemotherapy for Multiple Myeloma and Lymphoma

Öz:

Objective: We aimed to determine factors associated with hepatitis B virus (HBV) reactivation and vaccination success, and to evaluate the success of preemptive treatment in patients who received chemotherapy for multiple myeloma or lymphoma. Patients and Methods: This retrospective cross-sectional study conducted between December 2012 and January 2014. A total of 74 patients, who received systemic chemotherapy with a diag- nosis of multiple myeloma (n= 39) or lymphoma (n= 35) were included in the study. Results: The mean age was 53.5 ± 14.8 years. Reactivation was observed in four of the 28 patients followed for reactivation. All four patients were HBsAg positive at baseline (p< 0.001). Antibodies to HBsAg positivity was observed in only five of the 46 patients who received vacci- nation. All four of the patients who developed HBV reactivation were patients using prophylactic lamivudine treatment. After changing the prophylactic treatment regimen of these patients, HBV-DNA and alanine aminotransferase levels normalized and none of these patients died. Conclusion: In HBsAg-positive patients with multiple myeloma or lymphoma, pre-chemotherapy positivity for HBsAg was found to be associated with HBV reactivation. HBV-DNA monitoring at regular intervals may be useful for early detection of HBV reactivation and early initiation of antiviral therapy during chemotherapy.

Anahtar Kelime: Hepatitis B virus reactivation Multiple myeloma Lymphoma Chemotherapy Hepatitis B virus surface antigen

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estima- tions of worldwide prevalence of chronic hepatitis B virus infec- tion: A systematic review of data published between 1965 and 2013. Lancet 2015;386(10003):1546-55. https://doi.org/10.1016/ S0140-6736(15)61412-X
2. Wang B, Mufti G, Agarwal K. Reactivation of hepatitis B virus infection in patients with hematologic disorders. Haemato- logica 2019;104(3):435-43. https://doi.org/10.3324/haema- tol.2018.210252
3. Yilmaz B, Erdem D, Teker F, Goren I, Yildirim B, Kut E, et al. The effect of anticancer therapy on anti-hepatitis B antibody ti- tres in patients with haematological malignancies and sol- id tumours. J Int Med Res 2016;44(3):627-38. https://doi. org/10.1177/0300060516638992
4. Yeo W, Chan PK, Zhong S, Ho WM, Steinberg JL, Tam JS, et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: A prospective study of 626 patients with identification of risk factors. J Med Virol 2000;62(3):299-307. https://doi.org/10.1002/1096-9071(200011 )62:3<299::AID-JMV1>3.0.CO;2-0
5. Han JW, Yang H, Lee HL, Bae SH, Choi JY, Lee JW, et al. Risk fac- tors and outcomes of hepatitis B virus reactivation in hepatitis B surface antigen negative patients with hematological malig- nancies. Hepatol Res 2016;46(7):657-68. https://doi.org/10.1111/ hepr.12603
6. Fukushima N, Mizuta T, Tanaka M, Yokoo M, Ide M, Hisatomi T, et al. Retrospective and prospective studies of hepatitis B virus reac- tivation in malignant lymphoma with occult HBV carrier. Ann On- col 2009;20(12):2013-7. https://doi.org/10.1093/annonc/mdp230
7. Lalazar G, Rund D, Shouval D. Screening, prevention and treat- ment of viral hepatitis B reactivation in patients with haemato- logical malignancies. Br J Haematol 2007;136(5):699-712. https:// doi.org/10.1111/j.1365-2141.2006.06465.x
8. Marinone C, Mestriner M. HBV disease: HBsAg carrier and occult B infection reactivation in haematological setting. Dig Liver Dis 2011;43:49-56. https://doi.org/10.1016/S1590-8658(10)60692-5
9. Li J, Huang B, Li Y, Zheng D, Zhou Z, Liu J. Hepatitis B virus re- activation in patients with multiple myeloma receiving borte- zomib-containing regimens followed by autologous stem cell transplant. Leuk Lymphoma 2015;56(6):1710-7. https://doi. org/10.3109/10428194.2014.941833
10. Ataca Atilla P, Yalçıner M, Atilla E, İdilman R, Beksaç M. Hepatitis B reactivation rate and fate among multiple myeloma patients receiving regimens containing lenalidomide and/or bortezomib. Turk J Haematol 2019;36(4):266-73. https://doi.org/10.4274/tjh. galenos.2019.2019.0103
11. Dubovsky JA, Beckwith KA, Natarajan G, Woyach JA, Jaglowski S, Zhong Y, et al. Ibrutinib is an irreversible molecular in- hibitor of ITK driving a Th1-selective pressure in T lympho - cytes. Blood 2013;122(15):2539-49. https://doi.org/10.1182/ blood-2013-06-507947
12. De Jésus Ngoma P, Kabamba B, Dahlqvist G, Sempoux C, Lan- thier N, Shindano T, et al. Occult HBV reactivation induced by ibrutinib treatment: A case report. Acta Gastroenterol Belg 2015;78(4):424-6.
13. Tsukune Y, Sasaki M, Odajima T, Sunami K, Takei T, Moriuchi Y, et al. Incidence and risk factors of hepatitis B virus reactivation in patients with multiple myeloma in an era with novel agents: A nationwide retrospective study in Japan. Blood Cancer J 2017;7(12):631. https://doi.org/10.1038/s41408-017-0002-2
14. Meidani M, Khorvash F, Hemati S, Ashrafi F, Ataei B, Daneshmand D. The immune response of vaccination against hepatitis B virus in Iranian patients undergoing chemotherapy. Advanced Biomed- ical Research 2017;6:88. https://doi.org/10.4103/abr.abr_330_13
15. Nayak S, Gupta S, Kumar P, Jias M, Mandal P, Chandra J. A Study of immunogenicity of intensified hepatitis B vaccination in children being treated for acute lymphoblastic leukemia. Indian J Pediatr 2020;87(3):217-8. https://doi.org/10.1007/s12098-019-03147-4
16. Christopeit M, Schmidt-Hieber M, Sprute R, Buchheidt D, Hen- trich M, Karthaus M, et al. Prophylaxis, diagnosis and therapy of infections in patients undergoing high-dose chemotherapy and autologous haematopoietic stem cell transplantation. 2020 up - date of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medi- cal Oncology (DGHO). Ann Hematol 2021;100(2):321-36. https:// doi.org/10.1007/s00277-020-04297-8
17. Risum M, Barfod TS. Prophylaxis of reactivation of hepatitis B and hepatitis C virus infection in immunosuppressive therapy. Ug- eskr Laeger 2019;181(6):V08180568.
18. Gentile G, Andreoni M, Antonelli G, Sarmati L. Screening, moni- toring, prevention, prophylaxis and therapy for hepatitis B virus reactivation in patients with haematologic malignancies and pa- tients who underwent haematologic stem cell transplantation: A systematic review. Clin Microbiol Infect 2017;23(12):916-23. https://doi.org/10.1016/j.cmi.2017.06.024
19. Kusumoto S, Arcaini L, Hong X, Jin J, Kim WS, Kwong YL, et al. Risk of HBV reactivation in patients with B-cell lympho - mas receiving obinutuzumab or rituximab immunochemo - therapy. Blood 2019;133(2):137-46. https://doi.org/10.1182/ blood-2018-04-848044
20. Buti M, Manzano ML, Morillas RM, García-Retortillo M, Martín L, Prieto M, et al. Randomized prospective study evaluating ten- ofovir disoproxil fumarate prophylaxis against hepatitis B virus reactivation in anti-HBc-positive patients with rituximab-based regimens to treat hematologic malignancies: The Preblin study. PLoS One 2017;12(9):e0184550. https://doi.org/10.1371/journal. pone.0184550
21. Sarmati L, Andreoni M, Antonelli G, Arcese W, Bruno R, Coppola N, et al. Recommendations for screening, monitoring, preven- tion, prophylaxis and therapy of hepatitis B virus reactivation in patients with haematologic malignancies and patients who underwent haematologic stem cell transplantation-a position paper. Clin Microbiol Infect 2017;23(12):935-40. https://doi. org/10.1016/j.cmi.2017.06.023
22. Fonseca R, Bergsagel PL, Drach J, Shaughnessy J, Gutierrez N, Stewart AK, et al. International Myeloma Working Group molecu- lar classification of multiple myeloma: Spotlight review. Leukemia 2009;23(12):2210-21. https://doi.org/10.1038/leu.2009.174
23. Eichenauer DA, Aleman BMP, André M, Federico M, Hutchings M, Illidge T, et al. Hodgkin lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2018;29:19-29. https://doi.org/10.1093/annonc/mdy080
24. Al-Naeeb AB, Ajithkumar T, Behan S, Hodson DJ. Non-Hodgkin lymphoma. BMJ 2018;362:k3204. https://doi.org/10.1136/bmj. k3204
25. Huang H, Li X, Zhu J, Ye S, Zhang H, Wang W, et al. Entecavir vs lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiv- ing R-CHOP chemotherapy: A randomized clinical trial. JAMA 2014;312(23):2521-30. https://doi.org/10.1001/jama.2014.15704
26. Sodhi JS, Raja W, Zargar SA, Showkat A, Parveen S, Nisar S, et al. The efficacy of accelerated, multiple, double-dose hepatitis B vaccine against hepatitis B virus infection in cancer patients re- ceiving chemotherapy. Indian J Gastroenterol 2015;34(5):372-9. https://doi.org/10.1007/s12664-015-0595-y
27. Wands JR. Letter: Subacute and chronic active hepatitis after withdrawal of chemotherapy. Lancet 1975;2(7942):979. https:// doi.org/10.1016/S0140-6736(75)90391-8
28. Galbraith RM, Eddleston AL, Williams R, Zuckerman AJ. Fulmi- nant hepatic failure in leukaemia and choriocarcinoma related to withdrawal of cytotoxic drug therapy. Lancet 1975;2(7934):528- 30. https://doi.org/10.1016/S0140-6736(75)90897-1
29. Tavakolpour S, Alavian SM, Sali S. Hepatitis B reactivation dur - ing immunosuppressive therapy or cancer chemotherapy, man- agement, and prevention: A comprehensive review. Hepat Mon 2016;16(4):e35810. https://doi.org/10.5812/hepatmon.35810
30. Hsu CH, Hsu HC, Chen HL, Gao M, Yeh PY, Chen PJ, et al. Doxoru- bicin activates hepatitis B virus (HBV) replication in HBV-harbor- ing hepatoblastoma cells. A possible novel mechanism of HBV reactivation in HBV carriers receiving systemic chemotherapy. Anticancer Res 2004;24(5a):3035-40.
31. Tur-Kaspa R, Burk RD, Shaul Y, Shafritz DA. Hepatitis B virus DNA contains a glucocorticoid-responsive element. Proc Natl Acad Sci USA 1986;83(6):1627-31. https://doi.org/10.1073/ pnas.83.6.1627
32. Tsai YF, Yang CI, Du JS, Lin MH, Tang SH, Wang HC, et al. Rituximab increases the risk of hepatitis B virus reactivation in non-Hodg- kin lymphoma patients who are hepatitis B surface antigen-pos- itive or have resolved hepatitis B virus infection in a real-world setting: A retrospective study. Peer J 2019;7:e7481. https://doi. org/10.7717/peerj.7481
33. Paul S, Dickstein A, Saxena A, Terrin N, Viveiros K, Balk EM, et al. Role of surface antibody in hepatitis B reactivation in pa- tients with resolved infection and hematologic malignancy: A meta-analysis. Hepatology 2017;66(2):379-88. https://doi. org/10.1002/hep.29082
34. Ljungman P. Vaccination of immunocompromised patients. Clin Microbiol Infect 2012;18:93-9. https://doi.org/10.1111/j.1469- 0691.2012.03971.x
35. Yetgin S, Tunç B, Koç A, Toksoy HB, Ceyhan M, Kanra G. Two booster dose hepatitis B virus vaccination in patients with leu- kemia. Leuk Res 2001;25(8):647-9. https://doi.org/10.1016/ S0145-2126(00)00101-6
36. Zappulo E, Nicolini LA, Di Grazia C, Dominietto A, Lamparelli T, Gualandi F, et al. Efficacy of lamivudine prophylaxis in preventing hepatitis B virus reactivation in patients with resolved infection undergoing allogeneic SCT and receiving rituximab. Infection 2019;47(1):59-65. https://doi.org/10.1007/s15010-018-1214-5
37. Loglio A, Viganò M, Grossi G, Labanca S, Goldaniga M, Pompa A, et al. Lamivudine prophylaxis prevents hepatitis B virus reactiva- tion in anti-HBc positive patients under rituximab for non-Hodg- kin lymphoma. Dig Liver Dis 2019;51(3):419-24. https://doi. org/10.1016/j.dld.2018.08.024
38. Cao W, Wei J, Wang N, Xu H, Xiao M, Huang L, et al. Entecavir prophylaxis for hepatitis B virus reactivation in patients with CAR T-cell therapy. Blood 2020;136(4):516-9. https://doi.org/10.1182/ blood.2020004907
39. Liao YJ, Li YC, Lee SW, Wu CY, Yang SS, Yeh HZ, et al. Lamivudine versus entecavir in the rescue of chemotherapy-induced hepati- tis B flare-up. J Chin Med Assoc 2017;80(12):758-65. https://doi. org/10.1016/j.jcma.2017.07.009
40. KohrtH,OuyangD,KeeffeE.Systematicreview:Lamivudineproph- ylaxis for chemotherapy-induced reactivation of chronic hepati- tis B virus infection. Aliment Pharmacol Ther 2006;24(7):1003-16. https://doi.org/10.1111/j.1365-2036.2006.03081.x

APA	KUL A, Turan Erkek E, Nalcaci M (2023). Multipl Miyelom ve Lenfomalı Kemoterapi Alan Hastalarda Hepatit B Virüsü Reaktivasyonu ve Aşı Başarısı ile İlişkili Faktörler. , 20 - 28. 10.5578/llm.20239903
Chicago	KUL AYŞE NİLGÜN,Turan Erkek Esra,Nalcaci Meliha Multipl Miyelom ve Lenfomalı Kemoterapi Alan Hastalarda Hepatit B Virüsü Reaktivasyonu ve Aşı Başarısı ile İlişkili Faktörler. (2023): 20 - 28. 10.5578/llm.20239903
MLA	KUL AYŞE NİLGÜN,Turan Erkek Esra,Nalcaci Meliha Multipl Miyelom ve Lenfomalı Kemoterapi Alan Hastalarda Hepatit B Virüsü Reaktivasyonu ve Aşı Başarısı ile İlişkili Faktörler. , 2023, ss.20 - 28. 10.5578/llm.20239903
AMA	KUL A,Turan Erkek E,Nalcaci M Multipl Miyelom ve Lenfomalı Kemoterapi Alan Hastalarda Hepatit B Virüsü Reaktivasyonu ve Aşı Başarısı ile İlişkili Faktörler. . 2023; 20 - 28. 10.5578/llm.20239903
Vancouver	KUL A,Turan Erkek E,Nalcaci M Multipl Miyelom ve Lenfomalı Kemoterapi Alan Hastalarda Hepatit B Virüsü Reaktivasyonu ve Aşı Başarısı ile İlişkili Faktörler. . 2023; 20 - 28. 10.5578/llm.20239903
IEEE	KUL A,Turan Erkek E,Nalcaci M "Multipl Miyelom ve Lenfomalı Kemoterapi Alan Hastalarda Hepatit B Virüsü Reaktivasyonu ve Aşı Başarısı ile İlişkili Faktörler." , ss.20 - 28, 2023. 10.5578/llm.20239903
ISNAD	KUL, AYŞE NİLGÜN vd. "Multipl Miyelom ve Lenfomalı Kemoterapi Alan Hastalarda Hepatit B Virüsü Reaktivasyonu ve Aşı Başarısı ile İlişkili Faktörler". (2023), 20-28. https://doi.org/10.5578/llm.20239903

APA	KUL A, Turan Erkek E, Nalcaci M (2023). Multipl Miyelom ve Lenfomalı Kemoterapi Alan Hastalarda Hepatit B Virüsü Reaktivasyonu ve Aşı Başarısı ile İlişkili Faktörler. Türkiye'de Lösemi Lenfoma Miyelom Araştırmaları, 7(1), 20 - 28. 10.5578/llm.20239903
Chicago	KUL AYŞE NİLGÜN,Turan Erkek Esra,Nalcaci Meliha Multipl Miyelom ve Lenfomalı Kemoterapi Alan Hastalarda Hepatit B Virüsü Reaktivasyonu ve Aşı Başarısı ile İlişkili Faktörler. Türkiye'de Lösemi Lenfoma Miyelom Araştırmaları 7, no.1 (2023): 20 - 28. 10.5578/llm.20239903
MLA	KUL AYŞE NİLGÜN,Turan Erkek Esra,Nalcaci Meliha Multipl Miyelom ve Lenfomalı Kemoterapi Alan Hastalarda Hepatit B Virüsü Reaktivasyonu ve Aşı Başarısı ile İlişkili Faktörler. Türkiye'de Lösemi Lenfoma Miyelom Araştırmaları, vol.7, no.1, 2023, ss.20 - 28. 10.5578/llm.20239903
AMA	KUL A,Turan Erkek E,Nalcaci M Multipl Miyelom ve Lenfomalı Kemoterapi Alan Hastalarda Hepatit B Virüsü Reaktivasyonu ve Aşı Başarısı ile İlişkili Faktörler. Türkiye'de Lösemi Lenfoma Miyelom Araştırmaları. 2023; 7(1): 20 - 28. 10.5578/llm.20239903
Vancouver	KUL A,Turan Erkek E,Nalcaci M Multipl Miyelom ve Lenfomalı Kemoterapi Alan Hastalarda Hepatit B Virüsü Reaktivasyonu ve Aşı Başarısı ile İlişkili Faktörler. Türkiye'de Lösemi Lenfoma Miyelom Araştırmaları. 2023; 7(1): 20 - 28. 10.5578/llm.20239903
IEEE	KUL A,Turan Erkek E,Nalcaci M "Multipl Miyelom ve Lenfomalı Kemoterapi Alan Hastalarda Hepatit B Virüsü Reaktivasyonu ve Aşı Başarısı ile İlişkili Faktörler." Türkiye'de Lösemi Lenfoma Miyelom Araştırmaları, 7, ss.20 - 28, 2023. 10.5578/llm.20239903
ISNAD	KUL, AYŞE NİLGÜN vd. "Multipl Miyelom ve Lenfomalı Kemoterapi Alan Hastalarda Hepatit B Virüsü Reaktivasyonu ve Aşı Başarısı ile İlişkili Faktörler". Türkiye'de Lösemi Lenfoma Miyelom Araştırmaları 7/1 (2023), 20-28. https://doi.org/10.5578/llm.20239903